Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Norpace
(United States) [Available] ,Norpace CR
(United States) [Available]Synonyms :
Class :
Antidysrhythmics, Ia
Dosage Forms & Strengths Â
capsule Â
100mg Â
150mg Â
Capsule-CR Â
100mg Â
150mg Â
Dosage Forms & Strengths Â
Capsule Â
100mg Â
150mg Â
Capsule-ER Â
100mg Â
150mg Â
It may enhance QTc interval when combined with erythromycin stearate
It may enhance QTc interval when combined with perphenazine
It may enhance QTc interval when combined with epinephrine
when both drugs are combined, there may be an increase in qtc interval  
when both drugs are combined, there may be increased toxicity of disopyramide by QTC interval  
It may enhance QTc interval when combined with pentamidine
It may enhance QTc interval when combined with efavirenz
QTc interval is increased both by lenvatinib and azithromycin
both lapatinib and disopyramide increase the QTc interval
CYP3A strong enhancers of the small intestine may reduce the bioavailability of disopyramide
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may increase the bradycardic effect of Beta-Blockers
when bromazepam and disopyramide are used together, there is a potential reduction in the bromazepam's metabolism
When helometasone is used together with disopyramide, this leads to elevated risk or seriousness of hyperglycemia
When disopyramide is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
disopyramide leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When disopyramide is used together with diazoxide, this leads to reduction in therapeutic effectiveness of disopyramide
methylprednisolone hemisuccinateÂ
When methylprednisolone hemisuccinate is aided with disopyramide, this leads to elevated hyperglycemia risk
the effect of disopyramide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may enhance the serum concentration of CYP3A4 inhibitors
the activity of disopyramide may be increased due to pharmacodynamic synergism
the risk of hyperglycemia may be increased
When disopyramide is aided by hesperetin, it reduces hesperetin’s metabolism
Adverse drug reactions:  Â
Frequency Defined Â
1-10%Â
Urinary urgencyÂ
Urinary retentionÂ
Dry throatÂ
HypokalemiaÂ
Muscle weaknessÂ
Muscular painÂ
DyspneaÂ
ImpotenceÂ
Weight gainÂ
FlatulenceÂ
AnorexiaÂ
VomitingÂ
NauseaÂ
DermatosesÂ
PruritusÂ
Generalized rashÂ
Increased triglycerides and cholesterolÂ
Blurred visionÂ
Pregnancy warnings:    Â
Pregnancy category: CÂ
Breastfeeding warnings: Â
crosses into breast milkÂ
Pregnancy Categories:      Â
Patient Information Leaflet   Â
Generic Name: disopyramideÂ
Why do we use disopyramide?Â
Disopyramide belongs to the class Antidysrhythmics used to treat arrythmiaÂ
Â